Vitamin D and Cardiovascular Disease: Can Novel Measures of Vitamin D Status Improve Risk Prediction and Address the Vitamin D Racial Paradox?
Overview
Authors
Affiliations
Purpose Of Review: To provide a state-of-the-art update on some emerging measures of vitamin D status and discuss how assessment of these key vitamin D metabolites might improve prognostication of risk for cardiovascular disease (CVD) outcomes.
Recent Findings: Vitamin D deficiency is a highly prevalent condition and relatively easy to treat with supplementation and/or modest sunlight exposure. A substantial body of experimental and epidemiological evidence suggest that vitamin D deficiency is a risk factor for CVD. Most epidemiologic studies to date have focused on total 25-hydroxyvitamin D [25(OH)D] concentrations, which is the established marker of vitamin D stores. However, there is emerging evidence that other novel markers of vitamin D metabolism may better characterize 'true' vitamin D status. Some key novel measures include bioavailable 25(OH)D, free 25(OH)D, 1-25 dihydroxyvitamin D, 24,25-dihydroxyvitamin D3 [24,25(OH)D3], and ratio of 24,25(OH)D3 to 25(OH)D [the vitamin D metabolic ratio]. Utilization of these biomarkers may enhance understanding of the association between vitamin D and CVD risk, and may provide explanation for the observation that 25(OH)D is a stronger CVD risk factor in whites than blacks.
Summary: Novel measures of vitamin D status could potentially change clinical practice regarding how patients are currently screened for vitamin D status and defined as vitamin D deficient or not. However, whether measuring any of these alternate markers of vitamin D status can provide further insight regarding CVD risk beyond the traditionally measured 25(OH)D concentrations is uncertain at this time. This is an area where further research is strongly needed.
Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study.
Hsu S, Zelnick L, Bansal N, Brown J, Denburg M, Feldman H J Am Heart Assoc. 2023; 12(14):e028561.
PMID: 37421259 PMC: 10382125. DOI: 10.1161/JAHA.122.028561.
Michos E, Kalyani R, Blackford A, Sternberg A, Mitchell C, Juraschek S J Endocr Soc. 2022; 6(6):bvac065.
PMID: 35592513 PMC: 9113179. DOI: 10.1210/jendso/bvac065.
Alharazy S, Robertson M, Lanham-New S, Naseer M, Chaudhary A, Alissa E Endocr Connect. 2021; 10(12):1594-1606.
PMID: 34783311 PMC: 8679882. DOI: 10.1530/EC-21-0445.
Troja C, Hoofnagle A, Szpiro A, Stern J, Lin J, Winer R J Infect Dis. 2020; 224(1):123-132.
PMID: 33205195 PMC: 8491839. DOI: 10.1093/infdis/jiaa711.
Okereke O, Reynolds 3rd C, Mischoulon D, Chang G, Vyas C, Cook N JAMA. 2020; 324(5):471-480.
PMID: 32749491 PMC: 7403921. DOI: 10.1001/jama.2020.10224.